
Camlin Fine Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Blends business is expected to sustain robust growth with a healthy and substantial topline increase.
- Aroma segment's temporary weakness anticipated to be overcome in H2 with improved quality and quantity, especially in Vanillin products.
- Overall consolidated revenue remained stable despite Q1 softness, with demand recovering in Latin and South American markets.
- Pricing in Vanillin is seeing green shoots and some volume improvements are expected.
- Anti-dumping actions in US and Europe against Chinese manufacturers expected to positively impact Vanillin sales.
- The Vitafor acquisition opens new geographic markets and product avenues, anticipated to scale up over coming quarters.
- Management targets achieving double-digit EBITDA margin and revenue growth around Rs. 2,000 crore for the year FY25.
- Recovery in demand expected in next quarters, with cautious optimism about pricing stabilization and operational efficiencies improving margins.
See what Camlin Fine management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or future fundraising through debt or equity in the transcript.
- The company discussed expected CAPEX for repurposing plants (Rs 20-30 crore for China Heliotropin plant, Rs 2-3 million for Italy plant), but these costs are expected to be borne by partners or internally funded.
- Finance costs have not increased due to additional borrowing; the increase is mainly due to foreign exchange impact.
- No new mentions or plans of equity or debt fundraising were disclosed during the call.
See what Camlin Fine management said on order book — free account, 30 seconds.
Capex plans
Yes- Repurposing of China Heliotropin plant with expected CAPEX of Rs 20-30 crores, to be borne by the partner (no cash outflow for Camlin Fine Sciences). Timeline not specified.
- Italy plant repurposing with anticipated CAPEX of Rs 2-3 million, expected to take 6-9 months. Revenues post-repurposing to start next year with EBITDA margins of 10-12%.
- Acquisition of Vitafor Invest NV, Belgium completed on June 11, 2024, enabling expansion into Northern Africa and East European markets with synergies in blends business.
- No specific CAPEX mentioned related to the Vitafor acquisition, but integration and scaling up initiatives ongoing.
- No other immediate CAPEX or strategic investment details disclosed in the call.
Track Camlin Fine — get its next earnings analysis in your feed
How does Camlin Fine rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Camlin Fine rank in Chemicals & Petrochemicals?
Compare Camlin Fine against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Camlin Fine's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…